Post Content
Merck & Co., Inc. (NYSE:MRK) is one of the
10 Best Performing Dow Stocks So Far in 2026.
On March 31, 2026, Reuters announced that Infinimmune has signed an agreement with Merck & Co., Inc. (NYSE:MRK) to research and develop several antibody candidates, with potential milestone payments totaling $838 million. The deal includes an undisclosed upfront payment to Infinimmune. Merck & Co., Inc. (NYSE:MRK) retains exclusive rights to develop and commercialize the ensuing medicines.
Infinimmune announced that it will use its exclusive technology to screen vast volumes of human immune cells. It is discovering naturally existing antibodies and improving them with artificial intelligence methods. CEO of Infinimmune Wyatt McDonnell told Reuters that the technology promotes antibodies that have already been sculpted by human biology rather than creating them from scratch.
The firms will investigate various secret targets chosen by Merck & Co., Inc. (NYSE:MRK). McDonnell stressed that the relationship is not limited to a specific disease area. Infinimmune is also exploring internal early-stage treatments for moderate-to-severe eczema and other immune-related disorders.
Merck & Co., Inc. (NYSE:MRK) is a healthcare firm that provides health solutions through prescription medications, vaccines, biologic therapies, animal health, and consumer care products. It operates in three segments: pharmaceutical, animal health, and other.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.